Next Article in Journal
Transcriptomic Analysis Reveals Host miRNAs Correlated with Immune Gene Dysregulation during Fatal Disease Progression in the Ebola Virus Cynomolgus Macaque Disease Model
Previous Article in Journal
Are Faecal Microbiota Analyses on Species-Level Suitable Clinical Biomarkers? A Pilot Study in Subjects with Morbid Obesity
Previous Article in Special Issue
Serological Evidence of Natural Exposure to Tick-Borne Pathogens in Horses, Romania
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 9
Issue 3
10.3390/microorganisms9030663
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Impact of Tick-Borne Diseases on the Bone

by
Imran Farooq
1 and
Tara J. Moriarty
1,2,*
1
Faculty of Dentistry, University of Toronto, Toronto, ON M5G 1G6, Canada
2
Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON M5G 1G6, Canada
*
Author to whom correspondence should be addressed.
Microorganisms 2021, 9(3), 663; https://doi.org/10.3390/microorganisms9030663
Submission received: 28 November 2020 / Revised: 17 March 2021 / Accepted: 18 March 2021 / Published: 23 March 2021
(This article belongs to the Special Issue Advance in Tick-Borne Diseases Research)
Browse Figures
Versions Notes

Abstract

:
Tick-borne infectious diseases can affect many tissues and organs including bone, one of the most multifunctional structures in the human body. There is a scarcity of data regarding the impact of tick-borne pathogens on bone. The aim of this review was to survey existing research literature on this topic. The search was performed using PubMed and Google Scholar search engines. From our search, we were able to find evidence of eight tick-borne diseases (Anaplasmosis, Ehrlichiosis, Babesiosis, Lyme disease, Bourbon virus disease, Colorado tick fever disease, Tick-borne encephalitis, and Crimean–Congo hemorrhagic fever) affecting the bone. Pathological bone effects most commonly associated with tick-borne infections were disruption of bone marrow function and bone loss. Most research to date on the effects of tick-borne pathogen infections on bone has been quite preliminary. Further investigation of this topic is warranted.

1. Introduction

A wide range of bacterial, viral, and protozoan pathogens can be transmitted by ticks, which act as vectors transporting pathogens to hosts, including humans [1,2]. These pathogens are responsible for many known human diseases, including those described in Table 1 below.
One of the most essential structures in vertebrates is bone, which supports the body, protects vital organs and stores minerals [23]. Bone is a mixture of inorganic content (minerals primarily in the form of hydroxyapatite crystals), organic components such as collagen, cells and proteins, and water [24,25]. There are two major types of bone: (1) cortical (compact) and (2) trabecular (spongy, cancellous or porous). In trabecular bone, the spaces between mineralized bone trabecula are filled with bone marrow and fat tissue (Figure 1). Bone marrow is highly vascularized and innervated and is responsible for the production of red blood cells, granulocytes, platelets, monocytes and lymphocytes [26].
Bone in most parts of the body is renewed by a dynamic process called bony remodelling [27], which involves four basic steps: resorption, reversal, formation and resting (Figure 2). Bony remodelling is driven by counterbalancing activities of osteoclasts, which are responsible for bone resorption, and osteoblasts, which are responsible for bone building (apposition) [28].
Bone plays a complex and important role in immune responses, and local and systemic infections can also cause bone pathology [30,31,32]. Osteoblasts and osteocytes can regulate numbers and differentiation of B-cells and T-cells in bone marrow [33,34], and osteoclasts create the bone marrow cavity required for normal hematopoiesis [35]. Infections and conditions accompanied by systemic immune responses, such as inflammatory bowel disease, can cause bone loss because inflammatory cytokines can stimulate osteoclastogenesis and bone resorption [36]. Microbes also directly colonize bone, as a result of injury, surgery, implanted devices and hematogenous dissemination from more distant infection sites. In some cases, colonization is accompanied by infectious pathologies including bone marrow dysfunction and bone loss.
To the best of our knowledge, the effects of tick-borne infections on bone have not been reviewed previously. We surveyed the primary research literature for studies investigating the changes occurring in the bone structure and function during human tick-borne pathogen infections. We used PubMed and Google Scholar search engines and keywords “tick”, “vector”, “bone” and the names of individual human tick-borne diseases and pathogens. Conference abstracts and articles published in languages other than English were excluded. These searches retrieved 500+ unique results, of which 132 were finally selected based on their relevance to the investigated topic in this review. Tick-borne diseases associated with human bone phenotypes are listed in Table 2 and described in greater detail below.

2. Anaplasmosis (Formerly Human Granulocytic Ehrlichiosis)

Anaplasmosis [3] is caused by the Gram-negative intracellular bacterium A. phagocytophilum, which infects myeloid cells (neutrophils, megakaryocytes, mast cells) and endothelial cells [37,38,39]. A. phagocytophilum and related species can infect humans, cattle, deer, dogs, foxes, horses, wild and laboratory mice and sheep [40,41,42]. In humans, the most common signs and symptoms include fever, malaise, myalgia, headache, arthralgia, thrombocytopenia, leukopenia and less commonly anemia [3]. Complications can include respiratory illness, organ failure and death. Although A. phagocytophilum appears to typically be transmitted by ticks, transmission has been reported after contact with infected blood [43].
A. phagocytophilum is detected in the bone marrow of sheep, mice, deer, horses, dogs, and humans [40,41,42,44,45,46,47,48]. Infection in mice and humans often features peripheral cytopenias accompanied by bone marrow abnormalities associated with dyserythropoiesis, dysmegakaryopoiesis impaired red blood cell and platelet regeneration) and hemophagocytic lymphohistiocytosis [41,47,48,49,50,51,52,53]. There is some evidence that these cytopenias could result from peripheral processes including extravascular hemolysis [54], but peripheral cytopenias appear to primarily result from dyserythropoiesis and dysmegakaryopoiesis [41,47,48]. The molecular mechanisms underlying bone marrow dysfunction in anaplasmosis are not yet understood. In vitro, bone marrow progenitors belonging to monocytic and granulocytic lineages are prone to infection by A. phagocytophilum [55]. Animal studies suggest that myelosuppressive chemokines produced during anaplasmosis reduce bone marrow proliferation and differentiation [56]. The exposure of bone marrow cells to chemokines (IL-8 and MIP-1) decreases the proliferation and differentiation of myeloid progenitor cells leading to reduced hematopoiesis [57]. Substantial further research is needed to understand the mechanisms of bone marrow suppression and their consequences in disease progression and outcomes of anaplasmosis.

3. Ehrlichiosis

Ehrlichiosis is caused by multiple species from the Ehrlichia genus of obligate intracellular bacteria, including E. chaffeensis, E. ewingii and E. muris eauclairensis [58,59]. Ehrlichia mainly infects monocytes and neutrophils in dogs, rodents, and humans [8,60]. The signs and symptoms of ehrlichiosis are non-specific, similar to many tick-borne infections and include fever, chills, and a rash [61].
Ehrlichia have been detected in the bone marrow of dogs, cows, mice, and humans [62,63,64,65]. Infections in animals and humans feature monocytosis and cytopenias accompanied by abnormal bone marrow function, indicated by dyshematopoiesis and dyserythropoiesis [66,67,68]. Peripheral cytopenias marked by anemia, thrombocytopenia or neutropenia have been reported in animals and humans [62,63,64,65,66,67,68]. Although the mechanism by which ehrlichiosis causes cytopenias is not well established, it is believed that Ehrlichia can invade myeloid cells of the bone marrow, resulting in dyshematopoiesis causing cytopenias [69]. As a compensatory response to the developing cytopenias, an increased number of immature megakaryocytes are produced [70], possibly causing thrombocytopenia. Cyotopenias observed in ehrlichiosis could also result from hypocellular bone marrow [70], although the reason for its hypocellularity is not clear. During chronic Ehrlichia infections, cytokine-mediated immune suppression, decreased production of blood cells, and sequestration of erythrocytes can all play their part in decreased erythropoiesis [68]. Bone marrow abnormalities seen in ehrlichiosis could also be caused by the production of type I interferons (IFNα/β) that are produced in response to almost all the infections. During ehrlichial infections, IFNα/β induces bone marrow loss and impaired hematopoiesis by causing decreased proliferation of hematopoietic stem and progenitor cells [69]. Though an effort has been made to pinpoint the cause of bone marrow suppression during ehrlichiosis, these mechanisms are largely speculative, and further work is needed to determine their exact effects on the bone marrow causing dyshematopoiesis.

4. Babesiosis

Microscopic intracellular Babesia parasites cause babesiosis. Babesia species mostly infect erythrocytes in the host, causing haemolytic anemia, which is especially dangerous in older adults [71]. Mild to moderate forms of illness are usually accompanied by fever, fatigue, malaise, headache, and chills [72]. Complications of severe illness include respiratory distress, renal failure, coma, or death [72].
Babesia have been detected in bone marrow of cattle, mice, dogs, and humans [73,74,75,76,77]. Babesia are intraerythrocytic parasites [78] and the most significant bone marrow abnormality associated with babesiosis is dyserythropoiesis, leading to anemia [79]. Thrombocytopenia also occurs in both animals and humans but is a less common presentation than anemia in both species [80,81,82,83]. Babesia invasion of erythrocytes can lead to intravascular hemolysis [80]. The mechanisms by which Babesia suppresses bone marrow function are largely unknown.

5. Lyme Disease

Members of the B. burgdorferi species complex are extracellular spirochete bacteria that cause Lyme disease or Lyme borreliosis [11]. Early Lyme disease symptoms can include fever, chills, headache, sweating, joint pain, myalgia, swollen lymph nodes and erythema migrans skin rash. Untreated Lyme disease can have complications such as arthritis, endocarditis, and neuroborreliosis [11].
B. burgdorferi has been detected in the bone marrow of dogs, birds, mice and humans [84,85,86,87], and bone pain, erosion at articular surfaces, osteomyelitis and osteopenia have been reported [86,87,88,89,90,91,92,93,94,95,96,97]. B. burgdorferi infection in mice causes trabecular bone loss due to inhibition of bone apposition rather than bone resorption [86]. One plausible reason for this finding could be that B. burgdorferi infection causes an upregulation of tumor necrosis factor-alpha (TNF-α), IL-1, and IL-6 [98,99] that can cause suppression of osteoblastogenesis [100]. The bone infection caused by B. burgdorferi is an emerging area and requires further investigation to shed light on the exact mechanism behind this phenomenon, especially in terms of its effect on osteoblastogenesis.

6. Bourbon Virus Disease

Bourbon virus disease is caused by the recently discovered Bourbon virus [101]. Signs and symptoms of this disease resemble those of many other tick-borne diseases and include fever, sweating, headache, fatigue, myalgia and arthralgia [101].
Bourbon virus infection in humans and mice often features peripheral cytopenias including thrombocytopenia, leukopenia and lymphopenia indicating possible bone marrow suppression [101,102]. As Bourbon virus disease has been recently discovered, more investigation is needed to understand its impact on the bone.

7. Colorado Tick Fever Disease

Colorado tick fever virus (CTFV) can infect humans, rodents and some other mammals and is responsible for the rare CTF disease in humans [103,104,105]. CTF disease signs and symptoms include biphasic fever, chills, headache, fatigue, skin rash and peripheral cytopenias including leukopenia, anemia and thrombocytopenia [106,107].
CTFV can infect and persist in human and murine erythrocytes for extended periods [108]. The prolonged viremia associated with CTFV infection is possibly due to the prolonged persistence of CTFV in intra-erythrocytic locations [109]. CTFV can cause multilineage cytopenias by directly invading and replicating inside the bone marrow CD34+ stem cells [110]. As CD34+ stem cells are important part of the hematopoietic system [111], the replication of CTFV inside these cells is indicative of abnormal hematopoiesis and bone marrow suppression [110]. The CTFV infection can also affect the immature bone marrow cells and this infection can persist through their various stages of maturation [112]. Although various reasons for bone marrow suppression have been hypothesized in the literature, more investigative studies are recommended.

8. Tick-Borne Encephalitis

The tick-borne encephalitis (TBE) is caused by the TBE virus (TBEV) [113]. Many patients infected by TBEV remain asymptomatic. Symptomatic patients usually suffer from fever, headaches, body aches, malaise, nausea, and vomiting, with thrombocytopenia and leukopenia seen early in infection in humans, dogs and horses [114,115,116,117,118,119,120].
TBE virus has been detected in the bone marrow of animals and humans [121,122], but it is unknown if and how bone marrow infection contributes to peripheral cytopenias.

9. Crimean–Congo Hemorrhagic Fever

Crimean–Congo Hemorrhagic Fever (CCHF) is caused by the CCHF virus (CCHFV) [123]. Infection can result in multi-organ failure secondary to cytokine storm and hemorrhage and has a fatality rate ranging between 3% and 50% [124]. The most common signs and symptoms of CCHF include sudden fever, chills, and severe migraine-like headaches [125]. Less common symptoms are vomiting and haemorrhages [126].
CCHFV presence in the bone marrow is not reported in the literature. CCHFV infection features peripheral cytopenias that are marked by thrombocytopenia and leukopenia in animals and humans [127,128,129,130]. One fatal feature of CCHFV infection is hemophagocytic syndrome (HPS) that is characterized by excessive bleeding due to cytokine storm [131]. Uncontrolled hypercytokinemia leads to myelosuppression and vascular damage causing multiple organ failure and death [132]. It is not clear if peripheral cytopenias are secondary to bone marrow dysfunction or systemic immune pathologies, and more research is needed on this topic.

10. Conclusions

This review concludes that multiple tick-borne diseases can infect and cause pathology in bone and bone marrow. Mechanisms underlying bone pathology in many of these diseases have been under-investigated and further study of this topic is warranted.

Author Contributions

Conceptualization, I.F. and T.J.M.; methodology, I.F. and T.J.M.; investigation, I.F. and T.J.M.; data curation, I.F. and T.J.M.; writing—original draft preparation, I.F.; writing—review and editing, I.F. and T.J.M.; visualization, I.F.; supervision, T.J.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rochlin, I.; Toledo, A. Emerging tick-borne pathogens of public health importance: A mini-review. J. Med. Microbiol. 2020, 69, 781–791. [Google Scholar] [CrossRef]
  2. Rodino, K.G.; Theel, E.S.; Pritt, B.S. Tick-borne diseases in the United States. Clin. Chem. 2020, 66, 537–548. [Google Scholar] [CrossRef] [PubMed]
  3. Bakken, J.S.; Dumler, J.S. Human granulocytic anaplasmosis. Infect. Dis. Clin. N. Am. 2015, 29, 341–355. [Google Scholar] [CrossRef] [Green Version]
  4. Fillâtre, P.; Revest, M.; Tattevin, P. Crimean-Congo hemorrhagic fever: An update. Med. Mal. Infect. 2019, 49, 574–585. [Google Scholar] [CrossRef]
  5. Krasteva, S.; Jara, M.; Frias-De-Diego, A.; Machado, G. Nairobi Sheep Disease Virus: A Historical and Epidemiological Perspective. Front. Vet. Sci. 2020, 7, 419. [Google Scholar] [CrossRef] [PubMed]
  6. Ma, J.; Lv, X.-L.; Zhang, X.; Han, S.Z.; Wang, Z.D.; Li, L.; Sun, H.T.; Ma, L.X.; Cheng, Z.L.; Shao, J.W.; et al. Identification of a new orthocnairovirus associated with human febrile illness in China. Nat. Med. 2021, 27, 434–439. [Google Scholar] [CrossRef]
  7. Krause, P.J. Human babesiosis. Int. J. Parasitol. 2019, 49, 165–174. [Google Scholar] [CrossRef]
  8. Saito, T.B.; Walker, D.H. Ehrlichioses: An Important One Health Opportunity. Vet. Sci. 2016, 3, 20. [Google Scholar] [CrossRef] [Green Version]
  9. Brault, A.C.; Savage, H.M.; Duggal, N.K.; Eisen, R.J.; Staples, J.E. Heartland Virus Epidemiology, Vector Association, and Disease Potential. Viruses 2018, 10, 498. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Bopp, N.E.; Kaiser, J.A.; Strother, A.E.; Barrett, A.D.T.; Beasley, D.W.C.; Benassi, V.; Milligan, G.N.; Preziosi, M.P.; Reece, L.M. Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development. NPJ Vaccines 2020, 5, 111. [Google Scholar] [CrossRef]
  11. Steere, A.C.; Strle, F.; Wormser, G.P.; Hu, L.T.; Branda, J.A.; Hovius, J.W.; Li, X.; Mead, P.S. Lyme borreliosis. Nat. Rev. Dis. Primers 2016, 2, 16090. [Google Scholar] [CrossRef] [PubMed]
  12. Madison-Antenucci, S.; Kramer, L.D.; Gebhardt, L.L.; Kauffman, E. Emerging Tick-Borne Diseases. Clin. Microbiol. Rev. 2020, 33, e00083-18. [Google Scholar] [CrossRef] [PubMed]
  13. Sahni, A.; Fang, R.; Sahni, S.K.; Walker, D.H. Pathogenesis of Rickettsial Diseases: Pathogenic and Immune Mechanisms of an Endotheliotropic Infection. Annu. Rev. Pathol. 2019, 14, 127–152. [Google Scholar] [CrossRef] [Green Version]
  14. Piotrowski, M.; Rymaszewska, A. Expansion of Tick-Borne Rickettsioses in the World. Microorganisms 2020, 8, 1906. [Google Scholar] [CrossRef] [PubMed]
  15. Kemenesi, G.; Bányai, K. Tick-Borne Flaviviruses, with a Focus on Powassan Virus. Clin. Microbiol. Rev. 2019, 32, e00106-17. [Google Scholar] [CrossRef] [Green Version]
  16. Bhatia, B.; Fledmann, H.; Marzi, A. Kyasanur Forest Disease and Alkhurma Hemorrhagic Fever Virus-Two Neglected Zoonotic Pathogens. Microorganisms 2020, 8, 1406. [Google Scholar] [CrossRef]
  17. Shah, S.Z.; Jabbar, B.; Ahmed, N.; Rehman, A.; Nasir, H.; Nadeem, S.; Jabbar, I.; Rahman, Z.U.; Azam, S. Epidemiology, Pathogenesis, and Control of a Tick-Borne Disease- Kyasanur Forest Disease: Current Status and Future Directions. Front. Cell. Infect. Microbiol. 2018, 8, 149. [Google Scholar] [CrossRef] [Green Version]
  18. Corrin, T.; Greig, J.; Harding, S.; Young, I.; Mascarenhas, M.; Waddell, L.A. Powassan virus, a scoping review of the global evidence. Zoonoses Public Health 2018, 65, 595–624. [Google Scholar] [CrossRef]
  19. Velay, A.; Paz, M.; Cesbron, M.; Gantner, P.; Solis, M.; Soulier, E.; Argemi, X.; Martinot, M.; Hansmann, Y.; Fafi-Kremer, S. Tick-borne encephalitis virus: Molecular determinants of neuropathogenesis of an emerging pathogen. Crit. Rev. Microbiol. 2019, 45, 472–493. [Google Scholar] [CrossRef]
  20. Talagrand-Reboul, E.; Boyer, P.H.; Bergström, S.; Vial, L.; Boulanger, N. Relapsing Fevers: Neglected Tick-Borne Diseases. Front. Cell. Infect. Microbiol. 2018, 8, 98. [Google Scholar] [CrossRef] [Green Version]
  21. Eisen, R.J.; Kugeler, K.J.; Eisen, L.; Beard, C.B.; Paddock, C.D. Tick-Borne Zoonoses in the United States: Persistent and Emerging Threats to Human Health. ILAR J. 2017, 58, 319–335. [Google Scholar] [CrossRef] [Green Version]
  22. Telford, S.R.; Goethert, H.K. Ecology of Francisella tularensis. Annu. Rev. Entomol. 2020, 65, 351–372. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Su, N.; Yang, J.; Xie, Y.; Du, X.; Chen, H.; Zhou, H.; Chen, L. Bone function, dysfunction and its role in diseases including critical illness. Int. J. Biol. Sci. 2019, 15, 776–787. [Google Scholar] [CrossRef] [Green Version]
  24. Boskey, A.L. Bone composition: Relationship to bone fragility and antiosteoporotic drug effects. Bonekey Rep. 2013, 2, 447. [Google Scholar] [CrossRef] [Green Version]
  25. Feng, X. Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease. Curr. Chem. Biol. 2009, 3, 189–196. [Google Scholar]
  26. Travlos, G.S. Normal structure, function, and histology of the bone marrow. Toxicol. Pathol. 2006, 34, 548–565. [Google Scholar] [CrossRef] [PubMed]
  27. Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 2007, 13, 791–801. [Google Scholar] [CrossRef]
  28. Rucci, N. Molecular biology of bone remodelling. Clin. Cases Miner. Bone Metab. 2008, 5, 49–56. [Google Scholar]
  29. Raggat, L.J.; Partridge, N.C. Cellular and Molecular Mechanisms of Bone Remodeling. J. Biol. Chem. 2010, 285, 25103–25108. [Google Scholar] [CrossRef] [Green Version]
  30. Oliveira, T.C.; Gomes, M.S.; Gomes, A.C. The crossroads between infection and bone loss. Microorganisms 2020, 8, 1765. [Google Scholar] [CrossRef] [PubMed]
  31. Romanò, C.L.; Romanò, D.; Logoluso, N.; Drago, L. Bone and joint infections in adults: A comprehensive classification proposal. Eur. J. Orthop. Surg. Traumatol. 2011, 1, 207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Urish, K.L.; Cassat, J.E. Staphylococcus aureus osteomyelitis: Bone, bugs, and surgery. Infect. Immun. 2020, 88, e00932-19. [Google Scholar] [CrossRef]
  33. Tsukasaki, M.; Takayanagi, H. Osteoimmunology: Evolving concepts in bone-immune interactions in health and disease. Nat. Rev. Immunol. 2019, 19, 626–642. [Google Scholar] [CrossRef] [PubMed]
  34. Cain, C.J.; Rueda, R.; McLelland, B.; Collette, N.M.; Loots, G.G.; Manilay, J.O. Absence of sclerostin adversely affects B-cell survival. J. Bone Miner. Res. 2012, 27, 1451–1461. [Google Scholar] [CrossRef] [Green Version]
  35. Morrison, S.J.; Scadden, D.T. The bone marrow niche for haematopoietic stem cells. Nature 2014, 505, 327–334. [Google Scholar] [CrossRef] [Green Version]
  36. Bravenboer, N.; Oostlander, A.E.; van Bodegraven, A.A. Bone loss in patients with inflammatory bowel disease: Cause, detection and treatment. Curr. Opin. Gastroenterol. 2021, 37, 128–134. [Google Scholar] [CrossRef] [PubMed]
  37. Ojogun, N.; Barnstein, B.; Huang, B.; Oskeritzian, C.A.; Homeister, J.W.; Miller, D.; Ryan, J.J.; Carlyon, J.A. Anaplasma phagocytophilum infects mast cells via alpha1,3-fucosylated but not sialylated glycans and inhibits IgE-mediated cytokine production and histamine release. Infect. Immun. 2011, 79, 2717–2726. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Granick, J.L.; Reneer, D.V.; Carlyon, J.A.; Borjesson, D.L. Anaplasma phagocytophilum infects cells of the megakaryocytic lineage through sialylated ligands but fails to alter platelet production. J. Med. Microbiol. 2018, 57, 416–423. [Google Scholar] [CrossRef]
  39. Herron, M.J.; Ericson, M.E.; Kurtti, T.J.; Munderloh, U.G. The interactions of Anaplasma phagocytophilum, endothelial cells, and human neutrophils. Ann. N. Y. Acad. Sci. 2005, 1063, 374–382. [Google Scholar] [CrossRef]
  40. Almazán, C.; Fourniol, L.; Rouxel, C.; Alberdi, P.; Gandoin, C.; Lagrée, A.C.; Boulouis, H.J.; de la Fuente, J.; Bonnet, S.I. Experimental Ixodes ricinus-Sheep Cycle of Anaplasma phagocytophilum NV2Os Propagated in Tick Cell Cultures. Front. Vet. Sci. 2020, 7, 40. [Google Scholar] [CrossRef] [Green Version]
  41. Johns, J.L.; Discipulo, M.L.; Koehne, A.L.; Moorhead, K.A.; Nagamine, C.M. Influence of Genetic Background on Hematologic and Histopathologic Alterations during Acute Granulocytic Anaplasmosis in 129/SvEv and C57BL/6J Mice Lacking Type I and Type II Interferon Signaling. Comp. Med. 2017, 67, 127–137. [Google Scholar]
  42. Tate, C.M.; Mead, D.G.; Luttrell, M.P.; Howerth, E.W.; Dugan, V.G.; Munderloh, U.G.; Davidson, W.R. Experimental infection of white-tailed deer with Anaplasma phagocytophilum, etiologic agent of human granulocytic anaplasmosis. J. Clin. Microbiol. 2005, 43, 3595–3601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Annen, K.; Friedman, K.; Eshoa, C.; Horowitz, M.; Gottschall, J.; Straus, T. Two cases of transfusion-transmitted Anaplasma phagocytophilum. Am. J. Clin. Pathol. 2012, 137, 562–565. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Lewis, S.R.; Zimmerman, K.; Dascanio, J.J.; Pleasant, R.S.; Witonsky, S.G. Equine granulocytic anaplasmosis: A case report and review. J. Equine Vet. Sci. 2009, 29, 160–166. [Google Scholar] [CrossRef]
  45. Uehlinger, F.D.; Clancey, N.P.; Lofstedt, J. Granulocytic anaplasmosis in a horse from Nova Scotia caused by infection with Anaplasma phagocytophilum. Can. Vet. J. 2011, 52, 537–540. [Google Scholar] [PubMed]
  46. Khatat, S.E.; Culang, D.; Gara-Boivin, C. Granulocytic anaplasmosis in 2 dogs from Quebec. Can. Vet. J. 2018, 59, 663–667. [Google Scholar]
  47. Yi, J.; Kim, K.-H.; Ko, M.K.; Lee, E.Y.; Choi, S.J.; Oh, M.D. Human Granulocytic Anaplasmosis as a Cause of Febrile Illness in Korea Since at Least 2006. Am. J. Trop. Med. Hyg. 2017, 96, 777–782. [Google Scholar] [CrossRef] [Green Version]
  48. Marko, D.; Perry, A.M.; Ponnampalam, A.; Nasr, M.R. Cytopenias and clonal expansion of gamma/delta T-cells in a patient with anaplasmosis: A potential diagnostic pitfall. J. Clin. Exp. Hematop. 2017, 56, 160–164. [Google Scholar] [CrossRef] [Green Version]
  49. Stokes, W.; Lisboa, L.F.; Lindsay, L.R.; Fonseca, K. Case Report: Anaplasmosis in Canada: Locally Acquired Anaplasma phagocytophilum Infection in Alberta. Am. J. Trop. Med. Hyg. 2020, 103, 2478–2480. [Google Scholar] [CrossRef]
  50. Jereb, M.; Pecaver, B.; Tomazic, J.; Muzlovic, I.; Avsic-Zupanc, T.; Premru-Srsen, T.; Levicnik-Stezinar, S.; Karner, P.; Strle, F. Severe human granulocytic anaplasmosis transmitted by blood transfusion. Emerg. Infect. Dis. 2012, 18, 1354–1357. [Google Scholar] [CrossRef] [PubMed]
  51. Kim, S.W.; Kim, C.M.; Kim, D.M.; Yun, N.R. Manifestation of anaplasmosis as cerebral infarction: A case report. BMC Infect. Dis. 2018, 18, 409. [Google Scholar] [CrossRef] [Green Version]
  52. Parkins, M.D.; Church, D.L.; Jiang, X.Y.; Gregson, D.B. Human granulocytic anaplasmosis: First reported case in Canada. Can. J. Infect. Dis. Med. Microbiol. 2009, 20, e100–e102. [Google Scholar] [CrossRef]
  53. Borjesson, D.; Macnamara, K.; Johns, J.; Winslow, G. Anaplasma phagocytophilum and Ehrlichia muris induce cytopenias and global defects in hematopoiesis. Clin. Microbiol. Infect. 2009, 15, 66–67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Bexfield, N.H.; Villiers, E.J.; Herrtage, M.E. Immune-mediated haemolytic anaemia and thrombocytopenia associated with Anaplasma phagocytophilum in a dog. J. Small Anim. Pract. 2005, 46, 543–548. [Google Scholar] [CrossRef]
  55. Klein, M.B.; Miller, J.S.; Nelson, C.M.; Goodman, J.L. Primary bone marrow progenitors of both granulocytic and monocytic lineages are susceptible to infection with the agent of human granulocytic ehrlichiosis. J. Infect. Dis. 1997, 176, 1405–1409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Klein, M.B.; Hu, S.; Chao, C.C.; Goodman, J.L. The agent of human granulocytic ehrlichiosis induces the production of myelosuppressing chemokines without induction of proinflammatory cytokines. J. Infect. Dis. 2000, 182, 200–205. [Google Scholar] [CrossRef]
  57. Rikihisa, Y. Mechanisms of obligatory intracellular infection with Anaplasma phagocytophilum. Clin. Microbiol. Rev. 2011, 24, 469–489. [Google Scholar] [CrossRef] [Green Version]
  58. Cohen, S.B.; Yabsley, M.J.; Freye, J.D.; Dunlap, B.G.; Rowland, M.E.; Huang, J.; Dunn, J.R.; Jones, T.F.; Moncayo, A.C. Prevalence of Ehrlichia chaffeensis and Ehrlichia ewingii in ticks from Tennessee. Vector Borne Zoonotic Dis. 2010, 10, 435–440. [Google Scholar] [CrossRef] [Green Version]
  59. Pritt, B.S.; Allerdice, M.E.J.; Sloan, L.M.; Paddock, C.D.; Munderloh, U.G.; Rikihisa, Y.; Tajima, T.; Paskewitz, S.M.; Neitzel, D.F.; Hoang Johnson, D.K.; et al. Proposal to reclassify Ehrlichia muris as Ehrlichia muris subsp. muris subsp. nov. and description of Ehrlichia muris subsp. eauclairensis subsp. nov., a newly recognized tick-borne pathogen of humans. Int. J. Syst. Evol. Microbiol. 2017, 67, 2121–2126. [Google Scholar] [CrossRef] [PubMed]
  60. Ismail, N.; Bloch, K.C.; McBride, J.W. Human ehrlichiosis and anaplasmosis. Clin. Lab. Med. 2010, 30, 261–292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Olano, J.P.; Masters, E.; Hogrefe, W.; Walker, D.H. Human monocytotropic ehrlichiosis, Missouri. Emerg. Infect. Dis. 2003, 9, 1579–1586. [Google Scholar] [CrossRef] [PubMed]
  62. Dubie, T.; Mohammed, Y.; Terefe, G.; Muktar, Y.; Tesfaye, J. An insight review on canine ehrlichiosis with emphasis on its epidemiology and pathogenesity importance. Glob. J. Vet. Med. Res. 2014, 2, 59–67. [Google Scholar]
  63. Al-Badrani, B.A. Diagnostic study of ehrlichiosis in cattle of Mosul-Iraq. Bas. J. Vet. Res. 2013, 12, 87–97. [Google Scholar] [CrossRef]
  64. Saito, T.B.; Thirumalapura, N.R.; Shelite, T.R.; Rockx-Brouwer, D.; Popov, V.L.; Walker, D.H. An animal model of a newly emerging human ehrlichiosis. J. Infect. Dis. 2015, 211, 452–461. [Google Scholar] [CrossRef] [PubMed]
  65. Allen, M.B.; Pritt, B.S.; Sloan, L.M.; Paddock, C.D.; Musham, C.K.; Ramos, J.M.; Cetin, N.; Rosenbaum, E.R. First reported case of Ehrlichia ewingii involving human bone marrow. J. Clin. Microbiol. 2014, 52, 4102–4104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Qurollo, B.A.; Buch, J.; Chandrashekar, R.; Beall, M.J.; Breitschwerdt, E.B.; Yancey, C.B.; Caudill, A.H.; Comyn, A. Clinicopathological findings in 41 dogs (2008–2018) naturally infected with Ehrlichia ewingii. J. Vet. Intern. Med. 2019, 33, 618–629. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Tan, H.P.; Dumler, J.S.; Maley, W.R.; Klein, A.S.; Burdick, J.F.; Fred Poordad, F.; Thuluvath, P.J.; Markowitz, J.S. Human monocytic ehrlichiosis: An emerging pathogen in transplantation. Transplantation 2001, 71, 1678–1680. [Google Scholar] [CrossRef] [PubMed]
  68. MacNamara, K.C.; Racine, R.; Chatterjee, M.; Borjesson, D.; Winslow, G.M. Diminished hematopoietic activity associated with alterations in innate and adaptive immunity in a mouse model of human monocytic ehrlichiosis. Infect. Immun. 2009, 77, 4061–4069. [Google Scholar] [CrossRef] [Green Version]
  69. Smith, J.N.P.; Zhang, Y.; Li, J.J.; McCabe, A.; Jo, H.J.; Maloney, J.; MacNamara, K.C. Type I IFNs drive hematopoietic stem and progenitor cell collapse via impaired proliferation and increased RIPK1-dependent cell death during shock-like ehrlichial infection. PLoS Pathog. 2018, 14, e1007234. [Google Scholar] [CrossRef] [Green Version]
  70. Dumler, J.S.; Dawson, J.E.; Walker, D.H. Human ehrlichiosis: Hematopathology and immunohistologic detection of Ehrlichia chaffeensis. Hum Pathol. 1993, 24, 391–396. [Google Scholar] [CrossRef]
  71. Vannier, E.G.; Diuk-Wasser, M.A.; Ben, M.C.; Krause, P.J. Babesiosis. Infect. Dis. Clin. N. Am. 2015, 29, 357–370. [Google Scholar] [CrossRef] [Green Version]
  72. Joseph, J.T.; Roy, S.S.; Shams, N.; Visintainer, P.; Nadelman, R.B.; Hosur, S.; Nelson, J.; Wormser, G.P. Babesiosis in Lower Hudson Valley, New York, USA. Emerg. Infect. Dis. 2011, 17, 843–847. [Google Scholar] [CrossRef]
  73. Orinda, G.O.; Commins, M.A.; Waltisbuhl, D.J.; Goodger, B.V.; Wright, I.G. A study of autoantibodies to phosphatidyl-serine in Babesia bovis and Babesia bigemina infections in cattle. Vet. Immunol. Immunopathol. 1994, 40, 275–281. [Google Scholar] [CrossRef]
  74. Bhanot, P.; Parveen, N. Investigating disease severity in an animal model of concurrent babesiosis and Lyme disease. Int. J. Parasitol. 2019, 49, 145–151. [Google Scholar] [CrossRef] [PubMed]
  75. Lewis, D.C.; Meyers, K.M.; Callan, M.B.; Bücheler, J.; Giger, U. Detection of platelet-bound and serum platelet-bindable antibodies for diagnosis of idiopathic thrombocytopenic purpura in dogs. J. Am. Vet. Med. Assoc. 1995, 206, 47–52. [Google Scholar]
  76. Huang, S.; Zhang, L.; Yao, L.; Li, J.; Chen, H.; Ni, Q.; Pan, C.; Jin, L. Human babesiosis in Southeast China: A case report. Int. J. Infect. Dis. 2018, 68, 36–38. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Man, S.Q.; Qiao, K.; Cui, J.; Feng, M.; Fu, Y.F.; Cheng, X.J. A case of human infection with a novel Babesia species in China. Infect. Dis. Poverty 2016, 5, 28. [Google Scholar] [CrossRef] [Green Version]
  78. Zhao, L.; Jiang, R.; Jia, N.; Ning, N.; Zheng, Y.; Huo, Q.; Sun, Y.; Yuan, T.; Jiang, B.; Li, T.; et al. Human Case Infected with Babesia venatorum: A 5-Year Follow-Up Study. Open Forum Infect. Dis. 2020, 7, ofaa062. [Google Scholar] [CrossRef] [Green Version]
  79. Clark, I.A.; Jacobson, L.S. Do babesiosis and malaria share a common disease process? Ann. Trop. Med. Parasitol. 1998, 92, 483–488. [Google Scholar] [CrossRef]
  80. Orf, K.; Cunnington, A.J. Infection-related hemolysis and susceptibility to Gram-negative bacterial co-infection. Front Microbiol. 2015, 6, 666. [Google Scholar] [CrossRef] [PubMed]
  81. Scheepers, E.; Leisewitz, A.L.; Thompson, P.N.; Christopher, M.M. Serial haematology results in transfused and non-transfused dogs naturally infected with Babesia rossi. J. S. Afr. Vet Assoc. 2011, 82, 136–143. [Google Scholar] [CrossRef] [Green Version]
  82. Akel, T.; Mobarakai, N. Hematologic manifestations of babesiosis. Ann. Clin. Microbiol. Antimicrob. 2017, 16, 6. [Google Scholar] [CrossRef]
  83. Bullard, J.M.; Ahsanuddin, A.N.; Perry, A.M.; Lindsay, L.R.; Iranpour, M.; Dibernardo, A.; Van Caeseele, P.G. The first case of locally acquired tick-borne Babesia microti infection in Canada. Can. J. Infect. Dis. Med. Microbiol. 2014, 25, e87–e89. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Hovius, K.E.; Rijpkema, S.G.; Westers, P.; van der Zeijst, B.A.; van Asten, F.J.; Houwers, D.J. A serological study of cohorts of young dogs, naturally exposed to Ixodes ricinus ticks, indicates seasonal reinfection by Borrelia burgdorferi sensu lato. Vet. Q. 1999, 21, 16–20. [Google Scholar] [CrossRef]
  85. Cleveland, C.A.; Swanepoel, L.; Brown, J.D.; Casalena, M.J.; Williams, L.; Yabsley, M.J. Surveillance for Borrelia spp. in Upland Game Birds in Pennsylvania, USA. Vet. Sci. 2020, 7, 82. [Google Scholar] [CrossRef]
  86. Tang, T.T.; Zhang, L.; Bansal, A.; Grynpas, M.; Moriarty, T.J. The Lyme Disease Pathogen Borrelia burgdorferi Infects Murine Bone and Induces Trabecular Bone Loss. Infect. Immun. 2017, 85, e00781-16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Oksi, J.; Mertsola, J.; Reunanen, M.; Marjamäki, M.; Viljanen, M.K. Subacute multiple-site osteomyelitis caused by Borrelia burgdorferi. Clin. Infect. Dis. 1994, 19, 891–896. [Google Scholar] [CrossRef]
  88. Steere, A.C.; Schoen, R.T.; Taylor, E. The clinical evolution of Lyme arthritis. Ann. Intern. Med. 1987, 107, 725–731. [Google Scholar] [CrossRef]
  89. Schlesinger, P.A.; Duray, P.H.; Burke, B.A.; Steere, A.C.; Stillman, M.T. Maternal-fetal transmission of the Lyme disease spirochete, Borrelia burgdorferi. Ann. Intern. Med. 1985, 103, 67–68. [Google Scholar] [CrossRef] [PubMed]
  90. Houtman, P.M.; Tazelaar, D.J. Joint and bone involvement in Dutch patients with Lyme borreliosis presenting with acrodermatitis chronica atrophicans. Neth. J. Med. 1999, 54, 5–9. [Google Scholar] [CrossRef]
  91. Hovmark, A.; Asbrink, E.; Olsson, I. Joint and bone involvement in Swedish patients with Ixodes ricinus-borne Borrelia infection. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 1986, 263, 275–284. [Google Scholar] [PubMed]
  92. Kvasnicka, H.M.; Thiele, J.; Ahmadi, T. Bone marrow manifestation of Lyme disease (Lyme borreliosis). Br. J. Haematol. 2003, 120, 723. [Google Scholar] [CrossRef] [PubMed]
  93. Lawson, J.P.; Rahn, D.W. Lyme disease and radiologic findings in Lyme arthritis. AJR Am. J. Roentgenol. 1992, 158, 1065–1069. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Lawson, J.P.; Steere, A.C. Lyme arthritis: Radiologic findings. Radiology 1985, 154, 37–43. [Google Scholar] [CrossRef] [PubMed]
  95. Munson, E.; Nardelli, D.T.; Du-Chateau, B.K.; Callister, S.M.; Schell, R.F. Hamster and murine models of severe destructive Lyme arthritis. Clin. Dev. Immunol. 2012, 2012, 504215. [Google Scholar] [CrossRef] [PubMed]
  96. Schmitz, G.; Vanhoenacker, F.M.; Gielen, J. Unusual musculoskeletal manifestations of Lyme disease. JBR-BTR 2004, 87, 224–228. [Google Scholar]
  97. Steere, A.C. Musculoskeletal manifestations of Lyme disease. Am. J. Med. 1995, 98, 44S–48S. [Google Scholar] [CrossRef]
  98. Zlotnikov, N.; Javid, A.; Ahmed, M.; Eshghi, A.; Tang, T.T.; Arya, A.; Bansal, A.; Matar, F.; Parikh, M.; Ebady, R.; et al. Infection with the Lyme disease pathogen suppresses innate immunity in mice with diet-induced obesity. Cell. Microbiol. 2017, 19, e12689. [Google Scholar] [CrossRef] [PubMed]
  99. Isogai, E.; Isogai, H.; Kimura, K.; Hayashi, S.; Kubota, T.; Nishikawa, T.; Nakane, A.; Fujii, N. Cytokines in the serum and brain in mice infected with distinct species of Lyme disease Borrelia. Microb. Pathog. 1996, 21, 413–419. [Google Scholar] [CrossRef]
  100. Redlich, K.; Smolen, J.S. Inflammatory bone loss: Pathogenesis and therapeutic intervention. Nat. Rev. Drug Discov. 2012, 11, 234–250. [Google Scholar] [CrossRef]
  101. Kosoy, O.I.; Lambert, A.J.; Hawkinson, D.J.; Pastula, D.M.; Goldsmith, C.S.; Hunt, D.C.; Staples, J.E. Novel thogotovirus associated with febrile illness and death, United States, 2014. Emerg. Infect. Dis. 2015, 21, 760–764. [Google Scholar] [CrossRef] [PubMed]
  102. Bricker, T.L.; Shafiuddin, M.; Gounder, A.P.; Janowski, A.B.; Zhao, G.; Williams, G.D.; Jagger, B.W.; Diamond, M.S.; Bailey, T.; Kwon, J.H.; et al. Therapeutic efficacy of favipiravir against Bourbon virus in mice. PLoS Pathog. 2019, 15, e1007790. [Google Scholar] [CrossRef]
  103. Pace, E.J.; O’Reilly, M. Tickborne Diseases: Diagnosis and Management. Am. Fam. Physician 2020, 101, 530–540. [Google Scholar]
  104. Burgdorfer, W. Colorado tick fever. II. The behavior of Colorado tick fever virus in rodents. J. Infect. Dis. 1960, 107, 384–388. [Google Scholar] [CrossRef]
  105. Bowen, G.S.; Shriner, R.B.; Pokorny, K.S.; Kirk, L.J.; McLean, R.G. Experimental Colorado tick fever virus infection in Colorado mammals. Am. J. Trop. Med. Hyg. 1981, 30, 224–229. [Google Scholar] [CrossRef]
  106. Kadkhoda, K.; Semus, M.; Jelic, T.; Walkty, A. Case Report: A case of colorado tick fever acquired in Southwestern Saskatchewan. Am. J. Trop. Med. Hyg. 2018, 98, 891–893. [Google Scholar] [CrossRef] [Green Version]
  107. Centers for Disease Control and Prevention. Available online: https://www.cdc.gov/coloradotickfever/faqs.html (accessed on 1 March 2021).
  108. Oshiro, L.S.; Dondero, D.V.; Emmons, R.W.; Lennette, E.H. The development of Colorado tick fever virus within cells of the haemopoietic system. J. Gen. Virol. 1978, 39, 73–79. [Google Scholar] [CrossRef]
  109. Emmons, R.W.; Oshiro, L.S.; Johnson, H.N.; Lennette, E.H. Intra-erythrocytic location of Colorado tick fever virus. J. Gen. Virol. 1972, 17, 185–195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Philipp, C.S.; Callaway, C.; Chu, M.C.; Huang, G.H.; Monath, T.P.; Trent, D.; Evatt, B.L. Replication of Colorado tick fever virus within human hematopoietic progenitor cells. J. Virol. 1993, 67, 2389–2395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  111. AbuSamra, D.B.; Aleisa, F.A.; Al-Amoodi, A.S.; Jalal Ahmed, H.M.; Chin, C.J.; Abuelela, A.F.; Bergam, P.; Sougrat, R.; Merzaban, J.S. Not just a marker: CD34 on human hematopoietic stem/progenitor cells dominates vascular selectin binding along with CD44. Blood Adv. 2017, 1, 2799–2816. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  112. Emmons, R.W. Colorado tick fever along the Pacific slope of North America. Jap. J. Med. Sci. Biol. 1967, 20, 166–170. [Google Scholar] [PubMed]
  113. Government of Canada, Diseases and Conditions. Available online: https://www.canada.ca/en/public-health/services/diseases/tick-borne-encephalitis/causes-tick-borne-encephalitis.html (accessed on 1 March 2021).
  114. Barp, N.; Trentini, A.; Di-Nuzzo, M.; Mondardini, V.; Francavilla, E.; Contini, C. Clinical and laboratory findings in tick-borne encephalitis virus infection. Parasite Epidemiol. Control. 2020, 10, e00160. [Google Scholar] [CrossRef] [PubMed]
  115. Bogovic, P.; Strle, F. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J. Clin. Cases 2015, 3, 430–441. [Google Scholar] [CrossRef] [PubMed]
  116. Lotric-Furlan, S.; Strle, F. Thrombocytopenia--a common finding in the initial phase of tick-borne encephalitis. Infection 1995, 23, 203–206. [Google Scholar] [CrossRef] [PubMed]
  117. Lotric-Furlan, S.; Strle, F. Thrombocytopenia, leukopenia and abnormal liver function tests in the initial phase of tick-borne encephalitis. Zentralbl. Bakteriol. 1995, 282, 275–278. [Google Scholar] [CrossRef]
  118. Bühler, T.; Boos, N.; Leuppi-Taegtmeyer, A.B.; Berger, C.T. Febrile illness and bicytopenia within hours after tick-borne encephalitis booster vaccination. NPJ Vaccines 2019, 4, 52. [Google Scholar] [CrossRef] [Green Version]
  119. Ruzek, J.S.D. Tick-borne encephalitis in domestic animals. Acta Virol. 2020, 64, 223–229. [Google Scholar]
  120. Wilhelmsson, P.; Jaenson, T.G.T.; Olsen, B.; Waldenström, J.; Lindgren, P.E. Migratory birds as disseminators of ticks and the tick-borne pathogens Borrelia bacteria and tick-borne encephalitis (TBE) virus: A seasonal study at Ottenby Bird Observatory in South-eastern Sweden. Parasites Vectors 2020, 13, 607. [Google Scholar] [CrossRef]
  121. Mansfield, K.L.; Johnson, N.; Phipps, L.P.; Stephenson, J.R.; Fooks, A.R.; Solomon, T. Tick-borne encephalitis virus—A review of an emerging zoonosis. J. Gen. Virol. 2009, 90, 1781–1794. [Google Scholar] [CrossRef]
  122. Růžek, D.; Dobler, G.; Mantke, O.D. Tick-borne encephalitis: Pathogenesis and clinical implications. Travel Med. Infect. Dis. 2010, 8, 223–232. [Google Scholar] [CrossRef]
  123. Whitehouse, C.A. Crimean-Congo hemorrhagic fever. Antivir. Res. 2004, 64, 145–160. [Google Scholar] [CrossRef] [PubMed]
  124. Ergonul, O. Crimean-Congo hemorrhagic fever virus: New outbreaks, new discoveries. Curr. Opin. Virol. 2012, 2, 215–220. [Google Scholar] [CrossRef] [PubMed]
  125. Aksoy, D.; Barut, H.; Duygu, F.; Çevik, B.; Kurt, S.; Sümbül, O. Characteristics of headache and its relationship with disease severity in patients with Crimean-Congo hemorrhagic fever. Agri 2018, 30, 12–17. [Google Scholar] [CrossRef] [PubMed]
  126. Peyrefitte, C.; Marianneau, P.; Tordo, N.; Bouloy, M. Crimean-Congo haemorrhagic fever. Rev. Sci. Tech. 2015, 34, 391–401. [Google Scholar] [CrossRef]
  127. Bente, D.A.; Alimonti, J.B.; Shieh, W.J.; Camus, G.; Ströher, U.; Zaki, S.; Jones, S.M. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 2010, 84, 11089–11100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  128. Cross, R.W.; Prasad, A.N.; Borisevich, V.; Geisbert, J.B.; Agans, K.N.; Deer, D.J.; Fenton, K.A.; Geisbert, T.W. Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia and mild clinical disease in cynomolgus monkeys. PLoS Negl. Trop. Dis. 2020, 14, e0008637. [Google Scholar] [CrossRef]
  129. Swanepoel, R.; Gill, D.E.; Shepherd, A.J.; Leman, P.A.; Mynhardt, J.H.; Harvey, S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 1989, 11, S794–S800. [Google Scholar] [CrossRef]
  130. Cagatay, A.; Kapmaz, M.; Karadeniz, A.; Basaran, S.; Yenerel, M.; Yavuz, S.; Midilli, K.; Ozsut, H.; Eraksoy, H.; Calangu, S. Haemophagocytosis in a patient with Crimean Congo haemorrhagic fever. J. Med. Microbiol. 2007, 56, 1126–1128. [Google Scholar] [CrossRef] [Green Version]
  131. Fisgin, N.T.; Fisgin, T.; Tanyel, E.; Doganci, L.; Tulek, N.; Guler, N.; Duru, F. Crimean-Congo hemorrhagic fever: Five patients with hemophagocytic syndrome. Am. J. Hematol. 2008, 83, 73–76. [Google Scholar] [CrossRef]
  132. Morimoto, A.; Nakazawa, Y.; Ishii, E. Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management. Pediatr. Int. 2016, 58, 817–825. [Google Scholar] [CrossRef]
Microorganisms 09 00663 g001 550
Figure 1. Hematoxylin and eosin (H and E) stained decalcified section showing bony trabeculae of spongy bone with marrow spaces and fat tissue.
Figure 1. Hematoxylin and eosin (H and E) stained decalcified section showing bony trabeculae of spongy bone with marrow spaces and fat tissue.
Microorganisms 09 00663 g001
Microorganisms 09 00663 g002 550
Figure 2. Flow chart depicting sequence of events during bony remodelling process. Adapted from Raggat and Partridge [29].
Figure 2. Flow chart depicting sequence of events during bony remodelling process. Adapted from Raggat and Partridge [29].
Microorganisms 09 00663 g002
Table
Table 1. Human diseases caused by tick-borne pathogens.
Table 1. Human diseases caused by tick-borne pathogens.
BacterialViralParasitic
Anaplasmosis (Anaplasma phagocytophilum) [3]Nairoviral diseases: Crimean-Congo Hemorrhagic Fever (CCHFV) [4]; Nairobi Sheep Disease (NSDV) [5]; Songling Virus Disease (SGLV) [6]Babesiosis (Babesia microti, B. divergens, B. duncani, B. venatorum) [7]
Ehrlichiosis (Ehrlichia chaffeensis, E. ewingii, E. muris) [8]Phenuiviral diseases: Heartland Virus Disease (HRTV) [9]; Severe Fever with Thrombocytopenia Syndrome (SFTSV) [10]
Lyme Disease (Borreliella afzelii, B. burgdorferi sensu stricto, B. garinii, B. mayonii) [11] Orthomyxoviral diseases: Bourbon virus disease (BRBV) [12]
Rickettsioses, including Flinders Island (R. honei), Israeli (R. conoriisubsp. israelensis), Mediterranean (R. conoriisubsp. conorii), Japanese (R. japonica) and Rocky Mountain (R. rickettsii) Spotted Fevers; Indian (R. conoriisubsp. indica), Queensland (R. australis) and Siberian Tick Typhus (R. sibiricasubsp. sibirica); Far Eastern (R. heilongjiangensis) and Lymphangitis-Associated (R. sibirica subsp. mongolitimonae) Rickettsioses; African Tick Bite (R. rickettsii) and Astrakhan (R. conorii subsp. caspia) Fevers; SENLAT (R. raoultii) [13,14]Flaviviral diseases [15]: Alkhurma Hemorrhagic Fever (AHFV) [16]; Kyasanur Forest Disease (KFDV) [17]; Omsk Hemorrhagic Fever (OHFV) [15]; Powassan Disease (POWV) [15,18]; Tick-borne Encephalitis (TBEV) [19]
Tick-borne Relapsing Fever (Borrelia crocidurae, B. duttoni, B. hermsii, B. hispanica, B. miyamotoi, B. parkeri, B. persica, B. turicatae) [20]Reoviral diseases: Colorado Tick Fever Disease (CTFV); Eyach Virus Disease (EYAV) [21]
Tularemia (Francisella tularensis) [22]
Table
Table 2. Tick-borne diseases with reported human bone phenotypes.
Table 2. Tick-borne diseases with reported human bone phenotypes.
Tick-Borne DiseaseImpact on Bone
Disrupted Bone Marrow FunctionBone Loss
Anaplasmosis√-
Ehrlichiosis√-
Babesiosis√-
Lyme disease-√
Bourbon virus disease√-
Colorado tick fever disease√-
Tick-borne encephalitis√-
Crimean-Congo Hemorrhagic Fever√-
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Farooq, I.; Moriarty, T.J. The Impact of Tick-Borne Diseases on the Bone. Microorganisms 2021, 9, 663. https://doi.org/10.3390/microorganisms9030663

AMA Style

Farooq I, Moriarty TJ. The Impact of Tick-Borne Diseases on the Bone. Microorganisms. 2021; 9(3):663. https://doi.org/10.3390/microorganisms9030663

Chicago/Turabian Style

Farooq, Imran, and Tara J. Moriarty. 2021. "The Impact of Tick-Borne Diseases on the Bone" Microorganisms 9, no. 3: 663. https://doi.org/10.3390/microorganisms9030663

APA Style

Farooq, I., & Moriarty, T. J. (2021). The Impact of Tick-Borne Diseases on the Bone. Microorganisms, 9(3), 663. https://doi.org/10.3390/microorganisms9030663

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop